{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02515942: Phase 2 Interventional Completed Geographic Atrophy
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04447469: Phase 2/Phase 3 Interventional Completed COVID
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03804996: Phase 1 Interventional Completed B-Cell Lymphoma
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:cantuzumab ravtansine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01652482: Phase 2 Interventional Completed Colorectal Cancer
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04723394: Phase 3 Interventional Completed COVID-19
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04723394: Phase 3 Interventional Completed COVID-19
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01042379: Phase 2 Interventional Recruiting Breast Neoplasms
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:blontuvetmab [INN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN